scholarly journals Respiratory syncytial virus pneumonia in an adult cord blood transplant recipient during the SARS‐CoV‐2 outbreak

eJHaem ◽  
2021 ◽  
Author(s):  
Takaaki Konuma ◽  
Masamichi Isobe ◽  
Seiko Kato ◽  
Satoshi Takahashi ◽  
Yasuhito Nannya
Keyword(s):  
Respiratory Syncytial Virus ◽  
Transplant Recipient ◽  
Cord Blood ◽  
Cord Blood Transplant ◽  
Virus Pneumonia ◽  
Syncytial Virus

Treatment of Respiratory Syncytial Virus Pneumonia in a Lung Transplant Recipient: Case Report and Review of the Literature

2004 ◽  
Vol 24 (7) ◽  
pp. 932-938 ◽  
Author(s):  
Jeremy D. Flynn ◽  
Wendell S. Akers ◽  
Mikael Jones ◽  
Natasa Stevkovic ◽  
Thomas Waid ◽  
...  
Keyword(s):  
Case Report ◽  
Respiratory Syncytial Virus ◽  
Transplant Recipient ◽  
Lung Transplant ◽  
Lung Transplant Recipient ◽  
Review Of The Literature ◽  
Virus Pneumonia ◽  
Syncytial Virus

Severe Respiratory Syncytial Virus Pneumonia in an Adult Renal Transplant Recipient: Successful Treatment with Ribavirin

1990 ◽  
Vol 22 (1) ◽  
pp. 87-89 ◽  
Author(s):  
Helene Peigue-Lafeuille ◽  
Nicole Gazuy ◽  
Pierre Mignot ◽  
Patrice Deteix ◽  
Daniel Beytout ◽  
...  
Keyword(s):  
Respiratory Syncytial Virus ◽  
Renal Transplant ◽  
Transplant Recipient ◽  
Renal Transplant Recipient ◽  
Successful Treatment ◽  
Severe Respiratory Syncytial Virus ◽  
Virus Pneumonia ◽  
Syncytial Virus ◽  
Adult Renal Transplant Recipient

Respiratory Syncytial Virus Pneumonia in a Cardiac Transplant Recipient

1988 ◽  
Vol 158 (3) ◽  
pp. 650-651 ◽  
Author(s):  
J. T. Sinnott ◽  
J. P. Cullison ◽  
M. S. Sweeney ◽  
M. Hammond ◽  
D. A. Holt
Keyword(s):  
Respiratory Syncytial Virus ◽  
Transplant Recipient ◽  
Cardiac Transplant ◽  
Cardiac Transplant Recipient ◽  
Virus Pneumonia ◽  
Syncytial Virus

scholarly journals Efficacy and safety of interferon on neonates with respiratory syncytial virus pneumonia

2020 ◽  
Vol 20 (6) ◽  
pp. 1-1
Author(s):  
Lingyun He ◽  
Lu Yang ◽  
Hua Zhang ◽  
Qian Luo
Keyword(s):  
Respiratory Syncytial Virus ◽  
Efficacy And Safety ◽  
Virus Pneumonia ◽  
Syncytial Virus

scholarly journals Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation.

1996 ◽  
Vol 40 (11) ◽  
pp. 2555-2557 ◽  
Author(s):  
D M Lewinsohn ◽  
R A Bowden ◽  
D Mattson ◽  
S W Crawford
Keyword(s):  
Respiratory Syncytial Virus ◽  
Phase I ◽  
Phase I Study ◽  
Drug Exposure ◽  
The United States ◽  
Marrow Transplant ◽  
Transplant Recipients ◽  
Virus Pneumonia ◽  
Syncytial Virus ◽  
Clinically Significant

Respiratory syncytial virus (RSV) pneumonia in marrow transplant recipients is associated with significant mortality. Ribavirin is a nucleoside analog with activity against RSV and in its aerosolized formulation is the only drug approved for treatment of RSV pneumonia in the United States. The clinical use of aerosolized ribavirin has been limited by caregivers' concerns about drug exposure and potential teratogenic effects. Since there is lack of proven efficacy and safety of the aerosolized ribavirin in this setting, we performed a phase I study of intravenous ribavirin treatment. Between November 1993 and May 1994, 10 patients with clinically significant RSV pneumonia at the Fred Hutchinson Cancer Research Center were enrolled. Only 2 of the 10 survived (20%; 95% CI, 3-56). Two of the 10 patients developed acute hemolysis that necessitated discontinuation of the medication. In conclusion, treatment of marrow transplant recipients with RSV pneumonia with intravenous ribavirin did not improve mortality compared with historical controls treated with the aerosolized drug.

Sign in / Sign up

Export Citation Format

Share Document